Four years after the initial COVID-19 wave, one thing is becoming increasingly clear — for many people, the story never really ended.

A recent study published in Infection tracked healthcare workers in Switzerland and found that a significant percentage continue to experience long COVID symptoms years after their initial infection. At baseline, over 40% reported at least one persistent symptom, including fatigue, brain fog, and loss of smell or taste.

Even over time, while some symptoms improved, a considerable portion of participants still reported ongoing issues, highlighting how long COVID is not just a short-term complication but, for some, a chronic condition.

Long COVID Is Not Just “Recovery Taking Time”

What stands out from the data is that recovery is not always linear.

Many patients describe cycles of improvement followed by relapse-like symptoms. This makes it difficult to return to normal routines, maintain consistent work performance, or even sustain daily energy levels.

For healthcare workers in particular, this becomes an even bigger issue — not just personally, but system-wide, affecting workforce sustainability.

The Treatment Gap — And Why Patients Look Elsewhere

One of the biggest frustrations around long COVID is the lack of clearly defined treatment pathways.

While research continues, there is still no universally accepted standard treatment that directly targets long COVID itself. Most approaches focus on symptom management rather than addressing root causes.

Because of this, many patients have explored alternative or off-label approaches over the past few years.

There has been ongoing discussion around medications such as ivermectin and hydroxychloroquine, which were widely talked about during earlier phases of the pandemic. Some reports and smaller-scale studies suggested potential effects, although the topic remains highly debated and not universally accepted in mainstream clinical guidelines.

Similarly, ivermectin has also been the subject of broader research interest beyond infectious disease, including a growing number of studies exploring its potential role in oncology settings. Despite this, public awareness around these lines of research remains relatively limited.

What This Means Going Forward

The key takeaway is simple:

Long COVID is real, persistent, and still not fully understood.

For patients, this often means navigating uncertainty — balancing official medical guidance with personal experiences, symptom tracking, and sometimes trial-and-error approaches to management.

For the healthcare system, it highlights the need for:

• Long-term support frameworks
• Flexible return-to-work strategies
• Continued research into underlying mechanisms and treatment options

Final Thought

COVID may no longer dominate headlines the way it once did, but for many, its effects are ongoing.

The focus now isn’t just about infection — it’s about what comes after, and how long that “after” really lasts.